59 related articles for article (PubMed ID: 3987840)
1. Effect of prolonged expansion of marrow progenitor compartments following doxorubicin (ADR) on subsequent radiation tolerance.
Kovacs CJ; Johnke RM; Emma DA; Scarantino CW
Exp Hematol; 1985; 13 Suppl 16():89-94. PubMed ID: 3987840
[TBL] [Abstract][Full Text] [Related]
2. Long-term consequences of chemotherapeutic agents on hematopoiesis: development of altered radiation tolerance.
Kovacs CJ; Evans MJ; Hooker JL; Johnke RM
NCI Monogr; 1988; (6):45-9. PubMed ID: 3352788
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells.
OKunewick JP; Buffo MJ; Kociban DL
Exp Hematol; 1985; 13 Suppl 16():23-30. PubMed ID: 3987836
[TBL] [Abstract][Full Text] [Related]
4. Development of latent residual drug damage to the hematopoietic marrow during the subsequent growth of tumors.
Kovacs CJ; Johnke RM; Evans MJ; Emma DA; Hooker JL
Exp Hematol; 1986 Mar; 14(3):165-72. PubMed ID: 3948928
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of cytotoxic agents on hematopoietic progenitors.
Botnick LE; Hannon EC; Vigneulle R; Hellman S
Cancer Res; 1981 Jun; 41(6):2338-42. PubMed ID: 7237432
[TBL] [Abstract][Full Text] [Related]
6. Activity of 4'-epi-doxorubicin on normal hematopoietic precursor cells in mice.
Sobrero A; Muzzulini C; D'Amore F; Bogliolo G; Massa G; Ghio R; Pannacciulli I
Cancer Treat Rep; 1982 Dec; 66(12):2061-70. PubMed ID: 6958365
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 1 alpha (IL-1) and macrophage colony-stimulating factor (M-CSF) accelerate recovery from multiple drug-induced myelosuppression.
Kovacs CJ; Kerr JA; Daly BM; Evans MJ; Johnke RM
Anticancer Res; 1998; 18(3A):1805-12. PubMed ID: 9673408
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the sensitivities of human, canine, and murine hematopoietic precursor cells to adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Marsh JC
Cancer Res; 1979 Feb; 39(2 Pt 1):360-4. PubMed ID: 761207
[TBL] [Abstract][Full Text] [Related]
9. Altered radiosensitivity of hematopoietic stem cells by vincristine pretreatment: superoxide dismutase activity as a possible mechanism.
Johnke RM; Kovacs CJ; Loven DP; Abernathy RS; Hooker JL
NCI Monogr; 1988; (6):193-7. PubMed ID: 3352765
[TBL] [Abstract][Full Text] [Related]
10. Accelerated postirradiation recovery of hematopoietic marrow following priming with low doses of vincristine.
Johnke RM; Abernathy RS
Radiat Res; 1990 Jun; 122(3):234-40. PubMed ID: 2356276
[TBL] [Abstract][Full Text] [Related]
11. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.
Down JD; Ploemacher RE
Exp Hematol; 1993 Jul; 21(7):913-21. PubMed ID: 8100536
[TBL] [Abstract][Full Text] [Related]
12. Reduction of marrow hematopoietic progenitor and stem cell content is not sufficient for enhanced syngeneic engraftment.
Robinson S; van Os R; Sheridan T; Mauch P
Stem Cells; 2000; 18(2):93-101. PubMed ID: 10742381
[TBL] [Abstract][Full Text] [Related]
13. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow.
Slanicka Krieger M; Nissen C; Manz CY; Toksoz D; Lyman SD; Wodnar-Filipowicz A
Exp Hematol; 1998 May; 26(5):365-73. PubMed ID: 9590652
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential.
Traycoff CM; Cornetta K; Yoder MC; Davidson A; Srour EF
Exp Hematol; 1996 Feb; 24(2):299-306. PubMed ID: 8641356
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic precursor cells in mice treated with 4-demethoxydaunorubicin and doxorubicin.
Massa G; Bogliolo G; D'Amore F; Muzzulini C; Ghio R; Pannacciulli I
J Natl Cancer Inst; 1982 Jun; 68(6):971-6. PubMed ID: 6953276
[TBL] [Abstract][Full Text] [Related]
16. Temporal recovery of short-term repopulating HSC subpopulations in marrow following schedule-dependent administrations of IL-1 alpha and M-CSF.
Kovacs CJ; Evans MJ; Roberts C; Harrell J; Abernathy R; Gooya J; Johnke RM
Exp Hematol; 1995 Aug; 23(9):1016-23. PubMed ID: 7635181
[TBL] [Abstract][Full Text] [Related]
17. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
Wierenga PK; Konings AW
Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal.
van Os R; Robinson S; Sheridan T; Mauch PM
Stem Cells; 2000; 18(2):120-7. PubMed ID: 10742384
[TBL] [Abstract][Full Text] [Related]
19. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells.
Miller CL; Rebel VI; Lemieux ME; Helgason CD; Lansdorp PM; Eaves CJ
Exp Hematol; 1996 Feb; 24(2):185-94. PubMed ID: 8641340
[TBL] [Abstract][Full Text] [Related]
20. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
Jackson JD; Yan Y; Ewel C; Talmadge JE
Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
